TY - JOUR
T1 - Efficacy of vinblastine, bleomycin, methotrexate (VBM) combination chemotherapy with involved field radiotherapy in early stage (I-IIA) Hodgkin disease patients
AU - Martinelli, Giovanni
AU - Cocorocchio, E.
AU - Saletti, P. C.
AU - Orecchia, R.
AU - Bernier, J.
AU - Tradati, N.
AU - Santoro, P.
AU - Robertson, C.
AU - Peccatori, F. A.
AU - Zucca, E.
AU - Cavalli, F.
PY - 2003/11
Y1 - 2003/11
N2 - Vinblastine, bleomycin, methotrexate (VBM) combination chemotherapy (CT) with involved field radiotherapy (IFRT) was first described by the Stanford group as an active regimen in early stage Hodgkin's disease (HD). Here, we report our retrospective experience of a modified VBM schedule + IFRT in a similar group of patients. From 1988, 49 patients with stage I-IIA HD received vinblastine (VBL) 6 mg/m2 , bleomycin (BLM) 10IU/m2, methotrexate (MTX 30 mg/m2 day 1,8 every four weeks for three cycles; IFRT was delivered four weeks later followed by three additional cycles of VBM with a dose reduction of BLM (6IU/m2). The regimen was well tolerated, with grade 3-4 neutropenia occurring in 20 patients. No acute or late pulmonary toxicity was recorded in our series. Estimated Freedom from Progression (FFP) and Overall Survival (OS) at five years are 75% (95% CI, 60.1%-92.2%) and 85% (95% CI, 73.6%-98.1%), respectively. In this retrospective analysis, VBM + IFRT treatment with bleomycin dose reduction seems safe and active. Such combination could be considered as first line treatment for early stage HD patients with favorable prognosis and/or not suitable for anthracyclines-containing regimens.
AB - Vinblastine, bleomycin, methotrexate (VBM) combination chemotherapy (CT) with involved field radiotherapy (IFRT) was first described by the Stanford group as an active regimen in early stage Hodgkin's disease (HD). Here, we report our retrospective experience of a modified VBM schedule + IFRT in a similar group of patients. From 1988, 49 patients with stage I-IIA HD received vinblastine (VBL) 6 mg/m2 , bleomycin (BLM) 10IU/m2, methotrexate (MTX 30 mg/m2 day 1,8 every four weeks for three cycles; IFRT was delivered four weeks later followed by three additional cycles of VBM with a dose reduction of BLM (6IU/m2). The regimen was well tolerated, with grade 3-4 neutropenia occurring in 20 patients. No acute or late pulmonary toxicity was recorded in our series. Estimated Freedom from Progression (FFP) and Overall Survival (OS) at five years are 75% (95% CI, 60.1%-92.2%) and 85% (95% CI, 73.6%-98.1%), respectively. In this retrospective analysis, VBM + IFRT treatment with bleomycin dose reduction seems safe and active. Such combination could be considered as first line treatment for early stage HD patients with favorable prognosis and/or not suitable for anthracyclines-containing regimens.
KW - Bleomycin
KW - Combination chemotherapy vinblastine
KW - Early stage
KW - Hodgkin disease
KW - Radiotherapy
KW - State I and II
UR - http://www.scopus.com/inward/record.url?scp=10744219617&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=10744219617&partnerID=8YFLogxK
U2 - 10.1080/1042819031000123429
DO - 10.1080/1042819031000123429
M3 - Article
C2 - 14738143
AN - SCOPUS:10744219617
VL - 44
SP - 1919
EP - 1923
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
SN - 1042-8194
IS - 11
ER -